Neurogenic heterotopic ossification (NHO) is a severe complication after spinal cord injury. It is a progressive formation of new extra bone within surrounding joint tissue most commonly at the hip (97%). Without an adequate treatment this leads to complete restriction of mobility of the affected joint. Current treatments consist of administration of non-steroidal antirheumatics, radiation of the affected area and resection of the adverse ossification. Nevertheless, occurrence of local recurrences is not unusual. Despite numerous studies in vitro and in animal models the pathogenicity is not completely elucidated and therefore a specific therapy is still not available.
As preliminary work there were obtained bioptic samples from affected and non-affected tissues from 10 patients with a beginning NHO. These samples will be further processed in our laboratory and then gene expression will be externally analyzed using Microarray gene chip technique by a certified company (ATLAS Biolabs GmbH Berlin).
The evaluation of the large data pool as well as correlations to tissue histology and clinical laboratory parameter will be performed subsequently in the department of spine injury.
-cross sectoral-Type of hazard:
rehabilitationDescription, key words:
gene expression, ossification, hip joint, spine injury, microarray